Skip to main
NKTX

Nkarta, Inc. (NKTX) Stock Forecast & Price Target

Nkarta, Inc. (NKTX) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Nkarta Inc. is experiencing positive momentum in patient enrollment due to the decision to reincorporate standardized lymphodepletion with fludarabine, which is expected to enhance the efficacy of its therapies. The company is positioned as an attractive investment in the emerging field of allogeneic, engineered NK cell therapies, offering a more affordable valuation compared to its peers. Additionally, Nkarta's focus on harnessing the self-regulated cytotoxicity of NK cells aims to address significant limitations associated with existing CAR-T therapies, highlighting its potential for growth in the cancer treatment market.

Bears say

Nkarta Inc. is experiencing a notable decline in funding for research and development (R&D) and selling, general, and administrative (SG&A) expenses, with R&D spending down 14% sequentially and SG&A spending reduced by 48%, leading to concerns about its financial sustainability. Additionally, the upcoming protocol amendment for NKX019, which reintroduces fludarabine into the lymphodepletion regimen, is expected to limit the robustness of data interpretations due to a constrained patient population. Management's decision to delay preliminary data disclosures until FY26 to present a comprehensive dataset further emphasizes the uncertainties surrounding the company’s clinical progress and financial outlook.

Nkarta, Inc. (NKTX) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nkarta, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nkarta, Inc. (NKTX) Forecast

Analysts have given Nkarta, Inc. (NKTX) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Nkarta, Inc. (NKTX) has a Strong Buy consensus rating as of Jan 10, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nkarta, Inc. (NKTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.